Ublituximab Market Report 2025

The ublituximab market size has grown rapidly in recent years. It will grow from $1.11 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. Growth in the historic period was driven by increasing awareness of disease burden, rising adoption of monoclonal antibody therapies, growing healthcare expenditure, expansion of hospital and clinical infrastructure, and higher prevalence of autoimmune disorders.

The ublituximab market size is expected to see rapid growth in the next few years. It will grow to $2.0 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. Growth in the forecast period is expected to be supported by rising demand for targeted therapies, expansion of specialty care services, increased research funding, a growing patient population in emerging markets, and a greater number of healthcare partnerships. Key trends anticipated for the forecast period include advancements in monoclonal antibody therapies, developments in drug delivery systems, increased investment in research and development for new treatments, innovation in treatment protocols, and progress in digital health platforms.

The increasing incidence of autoimmune disorders is expected to drive growth in the ublituximab market in the coming years. Autoimmune disorders involve the immune system mistakenly attacking healthy cells or disruptions in blood cell production and function. The rise in these conditions is mainly due to enhanced diagnostic capabilities and greater awareness, as healthcare systems have improved their ability to detect previously undiagnosed cases through advanced testing and expanded screening programs. Ublituximab, a glycoengineered anti-CD20 monoclonal antibody, manages autoimmune disorders by selectively depleting harmful B cells, which reduces abnormal immune activity and malignant cell growth. For example, in November 2024, Versorgungsatlas.de, a government organization based in Germany, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61 percent. Therefore, the rising incidence of autoimmune disorders is supporting growth in the ublituximab market.

Key players in the ublituximab market are focusing on next-generation monoclonal antibodies to increase treatment effectiveness, minimize side effects, and improve patient convenience. These advanced antibodies are engineered for better targeting, potency, or safety, thereby enhancing treatment outcomes and offering more convenient dosing schedules. For instance, in January 2023, TG Therapeutics Inc., a biopharmaceutical company based in the United States, launched BRIUMVI (ublituximab-xiiy) for treating adults with relapsing forms of multiple sclerosis. The treatment offers a one-hour infusion and a comprehensive patient support program to boost accessibility and adherence. BRIUMVI is a glycoengineered anti-CD20 monoclonal antibody designed to efficiently eliminate B cells, lowering relapse rates and disease activity in patients with relapsing multiple sclerosis, while also reducing side effects and providing a more convenient dosing option compared to traditional therapies. The drug works by binding to a specific epitope on CD20-expressing B cells, causing their targeted removal through antibody-dependent cellular cytotoxicity and apoptosis, which helps regulate the autoimmune response behind multiple sclerosis.

In August 2023, TG Therapeutics Inc. partnered with Neuraxpharm Group to commercialize BRIUMVI outside the United States and expand its reach in Europe. This collaboration aims to make BRIUMVI accessible to patients beyond the U.S., utilizing Neuraxpharm’s extensive expertise in European neurology and established presence across more than 20 countries to ensure a swift and effective launch. TG Therapeutics benefits from upfront payments, milestone-based earnings, tiered royalties on sales, and retains strategic flexibility to regain commercial rights if control changes. Neuraxpharm Group is a pharmaceutical company based in Germany that specializes in treatments for central nervous system disorders.

Major players in the ublituximab market are Samsung Biologics Co. Ltd., Neuraxpharm Group GmbH, TG Therapeutics Inc.

North America was the largest region in the ublituximab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ublituximab report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ublituximab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Ublituximab is a monoclonal antibody that targets the CD20 protein on the surface of B-cells, helping to reduce abnormal or overactive B-cell activity. It binds to these cells and promotes their destruction through immune system mechanisms, such as antibody-dependent cellular cytotoxicity. Ublituximab is primarily developed for the treatment of certain blood cancers and for modulating immune responses to manage disease progression effectively.

The primary formulation types of ublituximab are intravenous (IV) and pre-filled syringes. Intravenous administration delivers medication directly into the bloodstream for fast and controlled treatment. Ublituximab is indicated for conditions such as chronic lymphocytic leukemia, multiple sclerosis, and non-Hodgkin lymphoma. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Key end-users include hospitals, specialty clinics, and research institutes.

The ublituximab market research report is one of a series of new reports that provides ublituximab market statistics, including ublituximab industry global market size, regional shares, competitors with the ublituximab market share, ublituximab market segments, market trends, and opportunities, and any further data you may need to thrive in the ublituximab industry. This ublituximab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ublituximab market consists of sales of azer-cel and tg-1701. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.